Serono Expands in MS
Executive Summary
Serono's in-licensing deal with Amgen for marketed multiple sclerosis drug mitoxantrone (Novantrone) is the Swiss group's latest move to broaden its MS franchise, currently dominated by interferon beta-1a (Rebif). Novantrone gives Serono a second marketed product in a market where competition--already hot--may soon get even hotter.